Uniting tofight skin cancerand save lives
We are a community of over 1,500 professionals dedicated to reducing the incidence and impact of skin cancer in New Zealand
Aotearoa New Zealand Melanoma Clinical Guidelines
4th edition now available
Leading the fight against skin cancer
Skin Cancer NZ is the leading organisation for skin cancer professionals in New Zealand.
We are working towards a future with fewer skin cancers, and where every person - no matter who they are or where they live - receives the best possible care.
By shaping strategy, defining best practice, supporting professionals and advocating for change, we are driving a nationwide effort to improve outcomes and strengthen how skin cancers are prevented, detected and treated across New Zealand.
Join the Skin Cancer NZ Foundation Club
A unique opportunity to be part of Skin Cancer NZ’s journey from the beginning. With only 100 places available, a one-off contribution will secure your spot as a founding member and help build a strong foundation for long-term impact.
Become a member
Skin Cancer NZ brings together health professionals, health promoters, researchers, policy makers, and advocates who are committed to improving skin cancer prevention, early detection and care.
Membership is free and takes less than a minute to complete.
Latest news
13 August 2026
Skin Cancer NZ is supporting a petition calling for a ban on commercial sunbeds in New Zealand – and we encourage our members and supporter to add their voices by signing it. The petition, submitted by Madison Keay, calls on the House of Representatives to ban the importation, sale, lease, hire and operation of sunbeds and tanning beds in New Zealand.10 August 2026
Researchers have developed and validated a new Melanoma Cancer Awareness Measure (M-CAM) questionnaire to assess how well the public recognises melanoma symptoms and risk factors. The tool could help identify gaps in awareness and support efforts to improve early detection.7 August 2026
A recent Australian study has found that the proportion of melanoma patients receiving sentinel lymph node biopsy (SLNB) has remained relatively low over time, despite changes in clinical guidelines. The study highlights differences in access to SLNB based on factors including age, melanoma characteristics, socioeconomic status, and where people live.With thanks to our Founding Members
Supporting a future with better skin cancer outcomes for all New Zealanders.
Already a member?
Log in to update your details and access member content. Contact us if you need help.